International Review of Ophthalmology ›› 2022, Vol. 46 ›› Issue (4): 336-340.doi: 10.3760/cma.j.issn.1673-5803.2022.04.009

Previous Articles     Next Articles

Application of adalimumab in non-infectious uveitis

Peng Yu 1, Qiu Xinwen 2, Ye Bo2, Chen Jiansu3   

  1. 1Aier School of Ophthalmology, Central South University, Changsha 410000, China; 2Nanchang Aier Eye Hospital, Nanchang 330000, China; 3Aier Eye Institute, Changsha 410000, China

  • Received:2021-10-09 Online:2022-08-22 Published:2022-08-22
  • Contact: Chen Jiansu, Email: chenjiansu2000@163.com
  • Supported by:
    Key R & D Program of Jiangxi Province (20203BBGL73193)

Abstract: Non-infectious uveitis (NIU) is a group of immune-mediated diseases with complex etiology and difficult treatment. Tumor necrosis factor-α (TNF-α) is the key pro-inflammatory factor in NIU. Adalimumab is a fully humanized monoclonal antibody targeting TNF-α, specifically binding to TNF-α and therefore blocking its induced downstream processes. Application of adalimumab in NIU including uveitis caused by Behcet's disease, Vogt-Koyanagi-Harada syndrome, ankylosing spondylitis-related uveitis, and children's uveitis can effectively reduce inflammation, the dosage of glucocorticoid, and the recurrence rate. Its safety has also been initially confirmed. Adalimumab is a suitable option for second-line treatment of NIU and shows great potential in the treatment of NIU. (Int Rev Ophthalmol, 2022, 46:  336-340)

Key words: non-infectious uveitis, tumor necrosis factor -α inhibitors, adalimumab